Aquipta Drug Interactions

CYP3A4 inhibitors: Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) can significantly increase systemic exposure to atogepant. Co-administration of atogepant with itraconazole resulted in increased exposure (C_max by 2.15-fold and AUC by 5.5-fold) of atogepant in healthy subjects (see Dosage & Administration). Changes in atogepant exposure when co-administered with weak or moderate CYP3A4 inhibitors are not expected to be clinically significant.
Transporter inhibitors: Organic anion transporting polypeptide (OATP) inhibitors (e.g., rifampicin, ciclosporin, ritonavir) can significantly increase systemic exposure to atogepant. Co-administration of atogepant with single dose rifampicin resulted in increased exposure (C_max by 2.23-fold and AUC by 2.85-fold) of atogepant in healthy subjects (see Dosage & Administration).
Frequently co-administered medicinal products: Co-administration of atogepant with oral contraceptive components ethinyl estradiol and levonorgestrel, paracetamol, naproxen, sumatriptan, or ubrogepant did not result in significant pharmacokinetic interactions for either atogepant or co-administered medicinal products. Co-administration with famotidine or esomeprazole did not result in clinically relevant changes of atogepant exposure.